|
|
|
|
| LEADER |
04649nma a2201153 u 4500 |
| 001 |
EB002156923 |
| 003 |
EBX01000000000000001295038 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
230515 ||| eng |
| 020 |
|
|
|a books978-3-0365-6109-7
|
| 020 |
|
|
|a 9783036561097
|
| 020 |
|
|
|a 9783036561103
|
| 100 |
1 |
|
|a Sjöwall, Christopher
|
| 245 |
0 |
0 |
|a Clinical Features and Long-Term Outcomes of Systemic Lupus Erythematosus
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2023
|
| 300 |
|
|
|a 1 electronic resource (208 p.)
|
| 653 |
|
|
|a genetics
|
| 653 |
|
|
|a outcome
|
| 653 |
|
|
|a trajectories
|
| 653 |
|
|
|a long-term prognosis
|
| 653 |
|
|
|a Afro-Caribbean
|
| 653 |
|
|
|a lupus
|
| 653 |
|
|
|a systemic lupus
|
| 653 |
|
|
|a outcome measures
|
| 653 |
|
|
|a Sjögren syndrome
|
| 653 |
|
|
|a hydroxychloroquine
|
| 653 |
|
|
|a infections
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a comorbidities
|
| 653 |
|
|
|a proteasome
|
| 653 |
|
|
|a fatigue
|
| 653 |
|
|
|a abnormal liver function tests
|
| 653 |
|
|
|a Systemic Lupus Erythematosus
|
| 653 |
|
|
|a Medicine / bicssc
|
| 653 |
|
|
|a qualitative research
|
| 653 |
|
|
|a polymorphisms
|
| 653 |
|
|
|a remission
|
| 653 |
|
|
|a low-disease activity
|
| 653 |
|
|
|a low disease activity
|
| 653 |
|
|
|a SLEDAI-2K
|
| 653 |
|
|
|a TNFSF4
|
| 653 |
|
|
|a MIR1279
|
| 653 |
|
|
|a mood disorders
|
| 653 |
|
|
|a chronic damage
|
| 653 |
|
|
|a clinical follow-up
|
| 653 |
|
|
|a end-stage renal disease
|
| 653 |
|
|
|a neoplasm
|
| 653 |
|
|
|a linear discriminant analysis
|
| 653 |
|
|
|a Ki/SL
|
| 653 |
|
|
|a long disease duration
|
| 653 |
|
|
|a mortality
|
| 653 |
|
|
|a autoantibodies
|
| 653 |
|
|
|a rheumatoid arthritis
|
| 653 |
|
|
|a COVID-19
|
| 653 |
|
|
|a cross-sectional studies
|
| 653 |
|
|
|a patient-reported outcomes
|
| 653 |
|
|
|a compliance
|
| 653 |
|
|
|a systemic lupus erythematosus
|
| 653 |
|
|
|a damage
|
| 653 |
|
|
|a liver biopsy
|
| 653 |
|
|
|a cancer
|
| 653 |
|
|
|a hospital admissions
|
| 653 |
|
|
|a survival
|
| 653 |
|
|
|a cardiovascular disease
|
| 653 |
|
|
|a quality of life
|
| 653 |
|
|
|a surveys and questionnaires
|
| 653 |
|
|
|a medication adherence
|
| 653 |
|
|
|a autoimmune liver diseases
|
| 653 |
|
|
|a patient perspective
|
| 653 |
|
|
|a primary biliary cholangitis
|
| 653 |
|
|
|a health-related quality of life
|
| 653 |
|
|
|a laboratory
|
| 653 |
|
|
|a disease activity
|
| 653 |
|
|
|a classification
|
| 653 |
|
|
|a pain
|
| 653 |
|
|
|a dehydroepiandrosterone
|
| 653 |
|
|
|a psychosocial
|
| 653 |
|
|
|a cluster analysis
|
| 653 |
|
|
|a autoimmune hepatitis
|
| 653 |
|
|
|a SLE
|
| 653 |
|
|
|a glucocorticoids
|
| 653 |
|
|
|a epidemiology
|
| 653 |
|
|
|a hepatic involvement
|
| 653 |
|
|
|a flare
|
| 653 |
|
|
|a lupus nephritis
|
| 653 |
|
|
|a patient outcome
|
| 700 |
1 |
|
|a Parodis, Ioannis
|
| 700 |
1 |
|
|a Sjöwall, Christopher
|
| 700 |
1 |
|
|a Parodis, Ioannis
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-6109-7
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/6567
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/96622
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a The clinical spectrum of systemic lupus erythematosus (SLE) is highly heterogeneous, ranging from mild disease, which can be limited to skin and joint involvement, to life-threatening conditions with renal impairment, severe cytopenias, central nervous system disease, and thromboembolic events. Apart from the host genetics, several environmental factors, such as sunlight, infections, drugs, and probably hormonal factors, can trigger the onset of symptoms related to SLE. Despite significant advances in our understanding of the pathophysiology and optimization of medical care, patients with SLE still have significant rates of premature mortality and many patients experience severe disease with increased risk of sustaining organ damage and having a reduced health-related quality of life. The development of effective drugs that can induce remission or low disease activity, the unanimous use of definitions of remission and low or high disease activity, flare, and response to therapy, the identification of non-invasive biomarkers of disease activity and long-term outcomes, and the implementation of SLE patients' perspectives as an integral part of the clinical assessment constitute only a few of the many unmet needs in the field of SLE.
|